Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Short-term Investments (2016 - 2023)

Bioadaptives' Short-term Investments history spans 6 years, with the latest figure at $11.0 for Q3 2023.

  • On a quarterly basis, Short-term Investments fell 65.62% to $11.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $11.0, a 65.62% decrease, with the full-year FY2022 number at $42.0, down 77.89% from a year prior.
  • Short-term Investments hit $11.0 in Q3 2023 for Bioadaptives, down from $21.0 in the prior quarter.
  • Over the last five years, Short-term Investments for BDPT hit a ceiling of $3278.0 in Q1 2021 and a floor of $11.0 in Q3 2023.
  • Historically, Short-term Investments has averaged $556.83 across 5 years, with a median of $264.0 in 2021.
  • Biggest five-year swings in Short-term Investments: crashed 96.3% in 2020 and later skyrocketed 1107.94% in 2021.
  • Tracing BDPT's Short-term Investments over 5 years: stood at $772.0 in 2019, then crashed by 42.49% to $444.0 in 2020, then tumbled by 57.21% to $190.0 in 2021, then tumbled by 77.89% to $42.0 in 2022, then plummeted by 73.81% to $11.0 in 2023.
  • Business Quant data shows Short-term Investments for BDPT at $11.0 in Q3 2023, $21.0 in Q2 2023, and $32.0 in Q1 2023.